Recent studies suggested that class II PI3Ks are directly involved in breast cancer progression independently of class I PI3K, opening the way for the development of new therapeutic strategies targeting this enigmatic class of PI3K in breast cancer. This evidence concerns the gene PIK3CA and breast carcinoma.